This document discusses forecasts for the global anti-obesity drugs market from 2018 to 2028. It analyzes the market by drug mechanism of action, innovator vs generic drugs, prescription vs OTC, and short-term vs long-term drugs. The market for other anti-obesity drugs is projected to grow from $73 million in 2017 to $5.9 billion in 2028, representing a compound annual growth rate of 48.9% over this period. Sales of the drug Qysmia are forecasted to increase from $86 million in 2017 to $1.25 billion in 2028, with a compound annual growth rate of 27.6% during this time. By 2028, China is projected to

1. / Page 86visiongain.com/industries/pharma
Global Anti-obesity Drugs Market Forecast 2018-2028: Mechanism of Action,
Innovator Drugs, Generics. Prescription Drugs, OTC, Duration of Therapy,
Incretin mimetics/GLP-1 agonists, SNDRIs, Lipase Inhibitors, Serotonin receptor
agonists, Sympathomimetic-GABA receptor agonists, Sympathomimetics,
Short-term Drugs, Long-term Drugs
cholecystokinin and peptide YY etc. have further strengthened the forecasted growth arte of this
market.
Table 4.13 Global Anti-obesity Other Drugs Market 2017-2028: Revenue
($m), AGR (%), CAGR (%)
2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
Others (Revenue,
$m)
73 101 133 194 292 448 680 1,037 1,577 2,438 3,812 5,904
AGR (%) 34.5% 37.8% 32.0% 46.0% 50.7% 53.2% 52.0% 52.4% 52.0% 54.6% 56.4% 54.9%
CAGR (%, 2017-22
& 2023-28)
43.7 53.4
CAGR (%, 2017-
27)
48.9
Source: Visiongain 2018
Figure 4.17 Global Anti-obesity Other Drugs Market 2017-2028: Revenue
($m), AGR (%)
Source: Visiongain 2018
0%
10%
20%
30%
40%
50%
60%
-
1,000
2,000
3,000
4,000
5,000
6,000
7,000
2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
AGR,%
Revenue,$m
Year

2. / Page 134visiongain.com/industries/pharma
Global Anti-obesity Drugs Market Forecast 2018-2028: Mechanism of Action,
Innovator Drugs, Generics. Prescription Drugs, OTC, Duration of Therapy,
Incretin mimetics/GLP-1 agonists, SNDRIs, Lipase Inhibitors, Serotonin receptor
agonists, Sympathomimetic-GABA receptor agonists, Sympathomimetics,
Short-term Drugs, Long-term Drugs
Table 5.9 Qysmia Sales Forecast 2017-2028: Revenue ($m), AGR (%), CAGR
(%)
2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
Revenue, $m 86 93 115 142 179 225 292 386 515 690 927 1,249
AGR (%) 9.0% 23.1% 24.1% 25.5% 26.1% 29.5% 32.5% 33.3% 34.0% 34.3% 34.8%
CAGR (%, 2017-22 & 2023-28) 21.4 33.8
CAGR (%, 2017-28) 27.6
Source: Visiongain 2018
Figure 5.17 Qysmia Sales Forecast 2017-2028: Revenue ($m), AGR (%)
Source: Visiongain 2018
0%
5%
10%
15%
20%
25%
30%
35%
40%
-
200
400
600
800
1,000
1,200
1,400
2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
AGR,%
Revenue,$m

3. / Page 200visiongain.com/industries/pharma
Global Anti-obesity Drugs Market Forecast 2018-2028: Mechanism of Action,
Innovator Drugs, Generics. Prescription Drugs, OTC, Duration of Therapy,
Incretin mimetics/GLP-1 agonists, SNDRIs, Lipase Inhibitors, Serotonin receptor
agonists, Sympathomimetic-GABA receptor agonists, Sympathomimetics,
Short-term Drugs, Long-term Drugs
In the global market, market share of China, India, Brazil, and Russia are expected to be 7.7%,
5.8%, 2.9%, and 1.1%, respectively, by 2028. Amongst the BRIC countries, the market share of
China, India, Brazil, and Russia are 43.8%, 33.3%, 16.8%, and 6.1%, respectively by 2028.
Figure 6.33 BRIC Anti-obesity Drugs Market Forecast by Region: Global
Market Share (%), 2028
Source: Visiongain 2018
Figure 6.34 BRIC Anti-obesity Drugs Market Forecast by Region: Market
Share (%), 2017
Source: Visiongain 2018
US
51.4%
EU5
13.6%
Japan
3.6% RoW
13.9%
China
7.7%
India
5.8%
Brazil
2.9%
Russia
1.1%
BRIC
8.3%
38.4%
32.5%
19.5%
9.6%
China
India
Brazil
Russia